Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

By E. Galanis, J. Buckner, M. Maurer, J. Kreisberg, K. Ballman, J. Boni, J. Peralba, R. Jenkins, S. Dakhil, R. Morton and 5 more. Journal of Clinical Oncology, 2005

711 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/2851f1ce22f0bd54345951f5919445c8a1880622

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

In Physiology

Citations in the corpus

Exciting New Advances in Neuro-Oncology (2010, background): “43 , 44 A clinical trial of the dual PI3K/mTOR inhibitor, XL765, in combination with temozolomide for GBM is currently underway, but no preliminary data have been reported to date.”
Potential therapeutic applications of autophagy (2007, background): “Rapamycin is suitable for long-term human use (for example, to prevent renal-transplant rejection) and rapamycin analogues are in Phase III trials for gliomas and advanced renal carcinom”
The roles of intracellular protein-degradation pathways in neurodegeneration (2006, background): “) and rapamycin analogues are in phase III trials for the treatment of glioma”
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma (2008, methodology): “While our trial was underway, a single-arm phase II study of the mTOR inhibitor CCI-779 reported that 20 of 65 patients with recurrent glioblastoma (36%) had radiographic improvement [39].”
Rapamycin alleviates toxicity of different aggregate-prone proteins. (2006, background): “Rapamycin was approved as an immunosuppressant drug in 1999 and its water-soluble analogues, such as CCI-779 and RAD001, are currently in phase III (CCI-779) and phase II (RAD001) clinical trials for cancer (43,44).”
Malignant astrocytic glioma: genetics, biology, and paths to treatment. (2007, background): “…(temsiro-limus) have shown minimal activity overall in GBM as well, although further analysis of tumor material and clinical parameters from sporadic responders may indicate prognostic features (Chang et al. 2005; Galanis et al. 2005; Cloughesy et al. 2006; Wen et al. 2006; Franceschi et al. 2007).”